drugset / Trial / NCT00329329

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

NCT00329329

Phase 1 Terminated 24 enrolled Agennix
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.

Timeline

Start
2006-05
Primary completion
2009-01
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule
Subject Satraplatin Other / unclassified Oral

Indications